Thrombosis Journal

Papers
(The TQCC of Thrombosis Journal is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis63
Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta‐analysis48
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory45
Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor43
Direct oral anticoagulant use in left ventricular thrombus40
Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity36
Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis36
Disseminated intravascular coagulation: new identity as endotheliopathy-associated vascular microthrombotic disease based on in vivo hemostasis and endothelial molecular pathogenesis33
Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review30
Proximal deep vein thrombosis and pulmonary embolism in COVID-19 patients: a systematic review and meta-analysis28
Fatal pulmonary arterial thrombosis in a COVID-19 patient, with asymptomatic history, occurred after swab negativization22
Possible involvement of Syndecan-1 in the state of COVID-19 related to endothelial injury22
Viscoelastometry for detecting oral anticoagulants22
Complement C5a induces the generation of neutrophil extracellular traps by inhibiting mitochondrial STAT3 to promote the development of arterial thrombosis21
Current status of treatment of cancer-associated venous thromboembolism21
NETosis and SARS-COV-2 infection related thrombosis: a narrative review20
Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-1920
Coagulopathy associated with COVID-19 – Perspectives & Preventive strategies using a biological response modifier Glucan20
High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study18
Pathological findings in rotation thromboelastometry associated with thromboembolic events in COVID-19 patients18
A case-report of widespread pulmonary embolism in a middle-aged male seven weeks after asymptomatic suspected COVID 19 infection16
Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers15
Switching of vascular cells towards atherogenesis, and other factors contributing to atherosclerosis: a systematic review15
Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intens14
Detailed histological analysis of a thrombectomy-resistant ischemic stroke thrombus: a case report14
Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia14
Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: a systematic review and meta-analysis14
Thromboembolic and hemorrhagic risks after vaccination against SARS-CoV-2: a systematic review and meta-analysis of randomized controlled trials14
A review of thromboembolic events in hospitalized COVID-19 patients13
Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms13
Factor V Leiden 1691G > A mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis13
Suspected heparin-induced thrombocytopenia in a COVID-19 patient on extracorporeal membrane oxygenation support: a case report13
Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review13
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis12
Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database12
Incidence of peripheral intravenous catheter phlebitis and its associated factors among patients admitted to University of Gondar hospital, Northwest Ethiopia: a prospective, observational study12
Peripherally inserted central venous catheter in upper extremities leads to an increase in D-dimer and deep vein thrombosis in lower extremities11
Point of care diagnostic of hypercoagulability and platelet function in COVID-19 induced acute respiratory distress syndrome: a retrospective observational study11
Autopsy and statistical evidence of disturbed hemostasis progress in COVID-19: medical records from 407 patients11
Predictors of long-term post-thrombotic syndrome following high proximal deep vein thrombosis: a cross-sectional study11
D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and metanalysis11
ADAMTS13 activity decreases in the early phase of trauma associated with coagulopathy and systemic inflammation: a prospective observational study11
Current and future strategies to monitor and manage coagulation in ECMO patients10
SARS-CoV-2 and pulmonary embolism: who stole the platelets?10
Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data10
Safety and efficacy of endovascular thrombectomy in acute ischemic stroke treated with anticoagulants: a systematic review and meta-analysis10
Maternal mortality following thromboembolism; incidences and prophylaxis strategies9
Clinical significance of neutrophil extracellular traps biomarkers in thrombosis9
Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India9
Incidence and characteristics of arterial thromboemboli in patients with COVID-199
Frequency of deep vein thrombosis at admission for acute stroke and associated factors: a cross-sectional study9
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism9
GST null polymorphisms may affect the risk of coronary artery disease: evidence from a meta-analysis9
Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study8
Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia8
Platelet adhesion in type 2 diabetes: impact of plasma albumin and mean platelet volume8
Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis8
Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore8
Successful venous thromboprophylaxis in a patient with vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report of the first reported case in Thailand8
Postpartum vertebral artery dissection: case report and review of the literature8
Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients8
Review article inferior vena cava thrombosis: a case series of patients observed in Taiwan and literature review8
Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study8
Prognostic Value of D-dimer in patients with acute coronary syndrome treated by percutaneous coronary intervention: a retrospective cohort study8
Malignant tumor is the greatest risk factor for pulmonary embolism in hospitalized patients: a single-center study8
Lupus anticoagulant hypoprothrombinemia syndrome associated with bilateral adrenal haemorrhage in a child: early diagnosis and intervention8
Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy8
Collagen-dependent platelet dysfunction and its relevance to either mitochondrial ROS or cytosolic superoxide generation: a question about the quality and functional competence of long-stored platelet7
Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer7
The impact on renal function after long-term use of anticoagulants in atrial fibrillation patients7
Correction to: Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis7
Thrombosis management in times of COVID-19 epidemy; a Dutch perspective7
Use of laboratory testing for prediction of postoperative bleeding volume in cardiovascular surgery7
Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia7
Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study7
Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study6
JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature6
Comparison of anticoagulated versus non-anticoagulated patients with intra-aortic balloon pumps6
Impact of oral anticoagulation therapy on postoperative atrial fibrillation outcomes: a systematic review and meta-analysis6
Calibrated automated thrombogram II: removing barriers for thrombin generation measurements6
Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated w6
Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report6
Identification and characterization of two SERPINC1 mutations causing congenital antithrombin deficiency6
Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT6
Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis6
Agitation-dependent biomechanical forces modulate GPVI receptor expression and platelet adhesion capacity during storage6
The predictive value of D-dimer test for venous thromboembolism during puerperium in women age 35 or older: a prospective cohort study6
Point of care ultrasound screening for deep vein thrombosis in critically ill COVID-19 patients, an observational study6
The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study6
Comparison of deep vein thrombosis risks in acute respiratory distress syndrome caused by COVID-19 and bacterial pneumonia: a retrospective cohort study6
Endovascular revascularization strategies using catheter-based thrombectomy versus conventional catheter-directed thrombolysis for acute limb ischemia6
Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients5
Therapeutic duplication of anticoagulants: a retrospective study of frequency and consequences in a tertiary referral hospital5
An evaluation of venous thromboembolism by whole-body enhanced CT scan for critical COVID-19 pneumonia with markedly rises of coagulopathy related factors: a case series study5
Feasibility of anticoagulation using low molecular-weight heparin during catheter-directed thrombolysis for lower extremity deep venous thrombosis5
Thrombin generation capacity is enhanced by low antithrombin activity and depends on the activity of the related coagulation factors5
A modified microchip-based flow chamber system for evaluating thrombogenicity in patients with thrombocytopenia5
Safety, efficacy and prognosis of anticoagulant therapy for portal vein thrombosis in cirrhosis: a retrospective cohort study5
Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis5
Long noncoding RNA TUG1 induces angiogenesis of endothelial progenitor cells and dissolution of deep vein thrombosis5
The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines5
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study5
Coagulopathy and its associated factors among patients with a bleeding diathesis at the University of Gondar Specialized Referral Hospital, Northwest Ethiopia5
Cardiovascular risk factors are associated with augmented thrombogenicity in healthy individuals: analysis using the Total Thrombus-formation Analysis System5
The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study5
0.036052942276001